



# Day 3

September 24, 2022 (Saturday)

| Time   | Topic   | Speaker   |
|--|---|---|
| <b>Session 7: Exosome as Therapeutics</b><br>Moderator: Tzou-Yien Lin 林奏延 / Hon-Kan Yip 葉漢根        |   |   |
| 08:30-08:50  | Exosomes Derived from Hypoxia Cultured Human Adipose Stem Cells Alleviate Articular Chondrocyte Inflammaging and OA Progress  | <b>Mei-Ling Ho 何美玲</b><br>Distinguished Professor, Department of Physiology, Orthopaedic Research Center, Kaohsiung Medical University  |
| 08:50-09:10  | Exosome Engineering for Active Targeting and Intracellular Delivery of Therapeutic Proteins: Realization from Concept   | <b>Chulhee Choi</b><br>C.E.O., ILIAS Biologics Incorporated, Korea  |
| 09:10-09:30  | Theragnostic of Extracellular Vesicles derived from Mesenchymal Stroma Cells, Leukocytes and Urine  | <b>Kuen-Der Yang 楊崑德</b><br>Director, Dept. of Research, Mackay Children's Hospital, Taipei Affiliated Prof., National Yang Ming Chiao-Tung University, and National Defense Medical Center |
| 09:30-09:40  | Panel Discussion  |   |
| <b>Session 8: Automatics for Cell Therapy</b><br>Moderator: Chii-Wann Lin 林啟萬 / Wann-Hsin Chen 陳婉昕 |   |   |
| 09:40-10:00  | Conducting Clinical Trial for Decompensated Liver Cirrhosis Using Cultured Autologous Bone Marrow Derived Mesenchymal Stem Cells -Self-Contained Cirrhosis Regeneration Therapy | <b>Taro Takami 高見太郎</b><br>Department of Gastroenterology and Hepatology Yamaguchi University Graduate School of Medicine, Japan  |
| 10:00-10:20  | Automated Cell Culture Systems for Manufacturing Cell Therapy Products  | <b>Hsin-Hsin Shen 沈欣欣</b><br>Deputy General Director of Biomedical Technology and Device Research Laboratories, Industrial Technology Research Institute                                    |
| 10:20-10:40  | Coffee Break  |   |
| <b>Session 9: Regulation in Asia</b><br>Moderator: Akihiro Shimosaka 下坂皓洋 / Shou-Mei Wu 吳秀梅        |   |   |
| 10:40-11:00  | The Current Regulation and Future Prospect on Regenerative Medicine   | <b>Shou-Mei Wu 吳秀梅</b><br>Director General, Taiwan Food and Drug Administration   |
| 11:00-11:15  | Current Status of Consideration to Revise the Regenerative Medicine Safety Act in Japan   | <b>Kiyoshi Okada 岡田潔</b><br>Project Associate Professor<br>Deputy General Manager<br>Osaka University Graduate School of Medicine<br>Osaka University Hospital, Japan                       |

| Time  | Topic  | Speaker  |
|---|--|--|
| 11:15-11:30   | Cell, Tissue and Gene Therapy Products Regulations and Global Regulatory Convergence                                     | <b>Kellathur Srinivasan</b><br>Director, Advanced Therapy Products Branch/ Medicinal Products Pre-market Cluster   Health Products Regulation Group, Singapore |
| 11:30-11:45   | Regulatory Framework and Current Status of Regenerative Medical Products in JAPAN  | <b>Shinichi Noda 野田慎一</b><br>Deputy Review Director, Office of Cellular and Tissue-based Products, PMDA Japan  |
| 11:45-12:00   | Updates on European Regulatory Frame for Advanced Therapy Medicinal Products   | <b>Maria Christina Galli</b><br>Istituto Superiore di Sanità, Italy  |
| 12:00-12:10   | Panel Discussion   |  |
| 12:10-13:00   | Lunch time & ACTO Committee meeting  |  |
| 13:00-14:00   | Corporate Symposium 5 & 6  |  |
| <b>Keynote Speech 8</b><br>Moderator: Oscar Kuang-Sheng Lee 李光申                                 |  |  |
| 14:00-14:30   | The Dawn of Molecular Medicine - Mastering Cell Reprogramming for Human Therapeutics                                     | <b>John Rasko</b><br>Head of Department,<br>Royal Prince Alfred Hospital/Sydney Local Health District<br>Australia   |
| <b>Session 10: Clinical Applications</b><br>Moderator: Keiya Ozawa 小澤敬也                         |  |  |
| 14:30-14:50   | Recent Advances in Gene Therapy for Hemophilia   | <b>Annette von Drygalski</b><br>Director, Hemophilia and Thrombosis Treatment Center/Professor of Medicine   |
| 14:50-15:10   | CRISPR/Cas Gene-Editing of Hematopoietic Stem Cells for Gene Therapy of Inherited Bone Marrow Failure Syndromes          | <b>Julia Sukokowa</b><br>Germany   |
| 15:10-15:30   | Coffee Break   |  |
| <b>Session 11: Industry Session I</b><br>Moderator: Akihiro Shimosaka 下坂皓洋                      |  |  |
| 15:30-15:50   | International Company Presentation   | <b>Masamitsu Harata 原田雅充</b><br>President, Human Life CORD Japan Inc., Tokyo, Japan  |
| 15:50-16:10   | Establishing a Global Organization for Commercial Manufacturing and 3D Bioreactor Platform for Large Scale Manufacturing | <b>Ayako Nomori, MBA 農守 亜矢子</b><br>Manager, Business Development,<br>Minaris Regenerative Medicine, Co., Ltd., Japan   |
| 16:10-16:30   | International Company Presentation   | <b>Jaeseung Lim</b><br>Chief Executive Officer & Chief Scientific Officer (Founder)<br>Cellatoz Therapeutics, Inc, Korea                                       |
| <b>Session 12: Industry Session II</b><br>Moderator: Camelia C. J. Chen 陳昭蓉 / Tzou-Yien Lin 林奏延 |  |  |
| 16:30-16:45   | The Multifaceted Roles of CDMO in Cell Therapy Development   | <b>Cyrus Yang</b><br>Taiwan Bio Therapeutics<br>台寶生醫股份有限公司   |



| Time  | Topic  | Speaker   |
|---|--|---|
| 16:45-17:00   | The Research and Development of Stemchymal   | <b>Chih-Yuan Ho 何智元</b><br>Steminent Biotherapeutics Inc.<br>仲恩生醫科技股份有限公司             |
| 17:00-17:15   | UnicoCell- Total Solution of Allogeneic Stem Cell Technology                                 | <b>Yi Pei Hung</b><br>UnicoCell BioMed Co., Ltd.<br>向榮生醫科技股份有限公司                      |
| 17:15-17:30   | Antibody-Conjugated Allogeneic Gamma Delta T Cell Biology and Clinical Application in Cancer | <b>Sonny Hsiao</b><br>Acepodia Biotechnologies, Limited<br>育世博生物科技股份有限公司              |
| 17:30-17:45   | Application of Adipose-Derived Stem Cells in Treating Disease                                | <b>Chuck Yang</b><br>Gwo Xi Stem Cell Applied Technology Co., Ltd.<br>國璽幹細胞應用技術股份有限公司 |
| 17:45-18:00   | Natural Killer Cells Potentiate the Clinical Anti-tumor Application                          | <b>James Chieh Liang Lin</b><br>Medigen Biotechnology Corp.<br>基亞生物科技股份有限公司           |
| <b>ACTO Report and Closing Remark (2023 ACTO Presentation)</b><br>Moderator: Yao-Chang Chen 陳耀昌 |  |   |
| 18:00-18:30   | ACTO Report and 2023 ACTO Presentation   | <b>Akihiro Shimosaka 下坂皓洋</b><br>ACTO Chairman, Japan                                 |